CD274 and neoplasm: Finally, in the phase III CheckMate 227 study, treatment-naïve NSCLC patients with PD-L1 expression on ≥1% of tumor cells were randomly assigned to treatment with ipilimumab and nivolumab, nivolumab monotherapy or chemotherapy [35].